News

News Subscription

Jan 13. 2026
Basilea joins INCATE to support antifungal innovation
Read more
Download
Jan 08. 2026
Basilea provides portfolio update and outlook
Read more
Download
Jan 07. 2026
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
Read more
Download
Dec 11. 2025
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
Read more
Download
Nov 04. 2025 / Ad hoc announcement
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
Read more
Download
Sep 25. 2025 / Ad hoc announcement
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
Read more
Download
Sep 16. 2025 / Ad hoc announcement
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Read more
Download
Aug 19. 2025 / Ad hoc announcement
Basilea on track with strong 2025 half-year results
Read more
Download
Aug 14. 2025 / Ad hoc announcement
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
Read more
Download
Jul 29. 2025
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
Read more
Download